Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabis extract therapeutics - MMJ International

Next Previous
Drug Profile

Research programme: cannabis extract therapeutics - MMJ International

Alternative Names: Cannabidiol-derived medicines - MMJ International Holding; Medical marijuana products - MMJ International Holdings; MMJ-001; MMJ-002

Latest Information Update: 28 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MMJ International Holdings
  • Class Antidementias; Antiparkinsonians; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Cannabinoid receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • No development reported Huntington's disease; Multiple sclerosis

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for preclinical development in Huntington's-disease in USA
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO, Capsule)
  • 10 May 2019 MMJ 002 receives Orphan Drug status for Huntington's disease in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top